180 related articles for article (PubMed ID: 29557506)
1. The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy.
Neidert MC; Kowalewski DJ; Silginer M; Kapolou K; Backert L; Freudenmann LK; Peper JK; Marcu A; Wang SS; Walz JS; Wolpert F; Rammensee HG; Henschler R; Lamszus K; Westphal M; Roth P; Regli L; Stevanović S; Weller M; Eisele G
Acta Neuropathol; 2018 Jun; 135(6):923-938. PubMed ID: 29557506
[TBL] [Abstract][Full Text] [Related]
2. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy.
Dutoit V; Herold-Mende C; Hilf N; Schoor O; Beckhove P; Bucher J; Dorsch K; Flohr S; Fritsche J; Lewandrowski P; Lohr J; Rammensee HG; Stevanovic S; Trautwein C; Vass V; Walter S; Walker PR; Weinschenk T; Singh-Jasuja H; Dietrich PY
Brain; 2012 Apr; 135(Pt 4):1042-54. PubMed ID: 22418738
[TBL] [Abstract][Full Text] [Related]
3. Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy.
Neidert MC; Schoor O; Trautwein C; Trautwein N; Christ L; Melms A; Honegger J; Rammensee HG; Herold-Mende C; Dietrich PY; Stevanović S
J Neurooncol; 2013 Feb; 111(3):285-94. PubMed ID: 23263746
[TBL] [Abstract][Full Text] [Related]
4. Tapasin and human leukocyte antigen class I dysregulation correlates with survival in glioblastoma multiforme.
Thuring C; Geironson L; Paulsson K
Anticancer Agents Med Chem; 2014; 14(8):1101-9. PubMed ID: 25175688
[TBL] [Abstract][Full Text] [Related]
5. Myelin-forming cell-specific cadherin-19 is a marker for minimally infiltrative glioblastoma stem-like cells.
Zorniak M; Clark PA; Kuo JS
J Neurosurg; 2015 Jan; 122(1):69-77. PubMed ID: 25361488
[TBL] [Abstract][Full Text] [Related]
6. Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens.
Rapp C; Warta R; Stamova S; Nowrouzi A; Geisenberger C; Gal Z; Roesch S; Dettling S; Juenger S; Bucur M; Jungk C; DaoTrong P; Ahmadi R; Sahm F; Reuss D; Fermi V; Herpel E; Eckstein V; Grabe N; Schramm C; Weigand MA; Debus J; von Deimling A; Unterberg A; Abdollahi A; Beckhove P; Herold-Mende C
Acta Neuropathol; 2017 Aug; 134(2):297-316. PubMed ID: 28332095
[TBL] [Abstract][Full Text] [Related]
7. LGR5 promotes tumorigenicity and invasion of glioblastoma stem-like cells and is a potential therapeutic target for a subset of glioblastoma patients.
Xie Y; Sundström A; Maturi NP; Tan EJ; Marinescu VD; Jarvius M; Tirfing M; Jin C; Chen L; Essand M; Swartling FJ; Nelander S; Jiang Y; Uhrbom L
J Pathol; 2019 Feb; 247(2):228-240. PubMed ID: 30357839
[TBL] [Abstract][Full Text] [Related]
8. Ion channel expression patterns in glioblastoma stem cells with functional and therapeutic implications for malignancy.
Pollak J; Rai KG; Funk CC; Arora S; Lee E; Zhu J; Price ND; Paddison PJ; Ramirez JM; Rostomily RC
PLoS One; 2017; 12(3):e0172884. PubMed ID: 28264064
[TBL] [Abstract][Full Text] [Related]
9. CD133+ glioblastoma stem-like cells induce vascular mimicry in vivo.
Chiao MT; Yang YC; Cheng WY; Shen CC; Ko JL
Curr Neurovasc Res; 2011 Aug; 8(3):210-9. PubMed ID: 21675958
[TBL] [Abstract][Full Text] [Related]
10. Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors.
Marcu A; Schlosser A; Keupp A; Trautwein N; Johann P; Wölfl M; Lager J; Monoranu CM; Walz JS; Henkel LM; Krauß J; Ebinger M; Schuhmann M; Thomale UW; Pietsch T; Klinker E; Schlegel PG; Oyen F; Reisner Y; Rammensee HG; Eyrich M
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599019
[TBL] [Abstract][Full Text] [Related]
11. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
Ueda R; Ohkusu-Tsukada K; Fusaki N; Soeda A; Kawase T; Kawakami Y; Toda M
Int J Cancer; 2010 Feb; 126(4):919-29. PubMed ID: 19728337
[TBL] [Abstract][Full Text] [Related]
12. The hypoxic peri-arteriolar glioma stem cell niche, an integrated concept of five types of niches in human glioblastoma.
Aderetti DA; Hira VVV; Molenaar RJ; van Noorden CJF
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):346-354. PubMed ID: 29684521
[TBL] [Abstract][Full Text] [Related]
13. Glioblastoma cancer stem cells--from concept to clinical application.
Stopschinski BE; Beier CP; Beier D
Cancer Lett; 2013 Sep; 338(1):32-40. PubMed ID: 22668828
[TBL] [Abstract][Full Text] [Related]
14. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy.
Marcu A; Bichmann L; Kuchenbecker L; Kowalewski DJ; Freudenmann LK; Backert L; Mühlenbruch L; Szolek A; Lübke M; Wagner P; Engler T; Matovina S; Wang J; Hauri-Hohl M; Martin R; Kapolou K; Walz JS; Velz J; Moch H; Regli L; Silginer M; Weller M; Löffler MW; Erhard F; Schlosser A; Kohlbacher O; Stevanović S; Rammensee HG; Neidert MC
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858848
[TBL] [Abstract][Full Text] [Related]
15. Identification of microRNAs differentially expressed in glioblastoma stem-like cells and their association with patient survival.
Sana J; Busek P; Fadrus P; Besse A; Radova L; Vecera M; Reguli S; Stollinova Sromova L; Hilser M; Lipina R; Lakomy R; Kren L; Smrcka M; Sedo A; Slaby O
Sci Rep; 2018 Feb; 8(1):2836. PubMed ID: 29434344
[TBL] [Abstract][Full Text] [Related]
16. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).
Kowalewski DJ; Schuster H; Backert L; Berlin C; Kahn S; Kanz L; Salih HR; Rammensee HG; Stevanovic S; Stickel JS
Proc Natl Acad Sci U S A; 2015 Jan; 112(2):E166-75. PubMed ID: 25548167
[TBL] [Abstract][Full Text] [Related]
17. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.
Shraibman B; Barnea E; Kadosh DM; Haimovich Y; Slobodin G; Rosner I; López-Larrea C; Hilf N; Kuttruff S; Song C; Britten C; Castle J; Kreiter S; Frenzel K; Tatagiba M; Tabatabai G; Dietrich PY; Dutoit V; Wick W; Platten M; Winkler F; von Deimling A; Kroep J; Sahuquillo J; Martinez-Ricarte F; Rodon J; Lassen U; Ottensmeier C; van der Burg SH; Thor Straten P; Poulsen HS; Ponsati B; Okada H; Rammensee HG; Sahin U; Singh H; Admon A
Mol Cell Proteomics; 2018 Nov; 17(11):2132-2145. PubMed ID: 30072578
[TBL] [Abstract][Full Text] [Related]
18. TRIM8 regulates stemness in glioblastoma through PIAS3-STAT3.
Zhang C; Mukherjee S; Tucker-Burden C; Ross JL; Chau MJ; Kong J; Brat DJ
Mol Oncol; 2017 Mar; 11(3):280-294. PubMed ID: 28100038
[TBL] [Abstract][Full Text] [Related]
19. HLA class I is most tightly linked to levels of tapasin compared with other antigen-processing proteins in glioblastoma.
Thuring C; Follin E; Geironson L; Freyhult E; Junghans V; Harndahl M; Buus S; Paulsson KM
Br J Cancer; 2015 Sep; 113(6):952-62. PubMed ID: 26313662
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy targeting glioma stem cells--insights and perspectives.
Li Z; Lee JW; Mukherjee D; Ji J; Jeswani SP; Black KL; Yu JS
Expert Opin Biol Ther; 2012 Feb; 12(2):165-78. PubMed ID: 22200324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
